Terminated PHASE3 INTERVENTIONAL 3-arm NCT00332657

Anecortave Acetate Risk Reduction Trial (AART)

Sponsor: Alcon Research

Conditions AMD

Interventions Anecortave Acetate Sterile Suspension, 30 mg/mL Anecortave Acetate Sterile Suspension, 60 mg/mL Anecortave Acetate Vehicle

Updated 8 times since 2017 Last updated: Nov 27, 2012 Started: Sep 30, 2006 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Management Decision

Listed as NCT00332657, this PHASE3 trial focuses on AMD and remains terminated or withdrawn. Sponsored by Alcon Research, it has been updated 8 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE3
Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Apr 2022 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research

Data source: Alcon Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangalore, India